Fixed-dose combinations for emerging treatment of pain

被引:19
|
作者
Raffa, Robert B. [1 ]
Tallarida, Ronald J. [2 ]
Taylor, Robert, Jr. [3 ]
Pergolizzi, Joseph V., Jr. [2 ,4 ,5 ]
机构
[1] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA
[2] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA
[3] NEMA Res, Naples, FL USA
[4] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
[5] Georgetown Univ, Sch Med, Dept Anesthesiol, Washington, DC USA
关键词
analgesic; combination therapy; fixed-dose; isobole; pain; NEUROPATHIC PAIN; DOUBLE-BLIND; PHASE-III; ANALGESIC TRAMADOL; DESCENDING CONTROL; PLACEBO; RELEASE; MODEL; NOREPINEPHRINE; MODULATION;
D O I
10.1517/14656566.2012.668531
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Pain is a large and growing medical need that is not currently being fully met, primarily due to the shortcomings of existing analgesics (insufficient efficacy or limiting side-effects). Better outcomes might be achieved using a combination of analgesics. The ratio of the combinations matters and should therefore be evaluated using rigorous quantitative and well-documented analysis. Areas covered: Advances have been made in understanding the normal physiology of pain processing, including the pathways and neurotransmitters involved. Insight has also been gained about physiological processes that can lead to different 'types' of pain and the transition from acute to chronic pain conditions. This 'multimechanistic' nature of most pains is better matched using a 'multimechanistic' rather than 'monomechanistic' analgesic approach. Such an approach - and the experimental design and data analysis to assess optimal combinations - is described and discussed. Expert opinion: There are sound pharmacologic, as well as practical, reasons for using combinations of drugs to treat pain. Compared with single agents, they offer a potential better match to the underlying pain physiology and thus greater efficacy or reduced side effects. The optimal efficacy and side-effect ratio must be determined in a scientifically rigorous manner.
引用
收藏
页码:1261 / 1270
页数:10
相关论文
共 50 条
  • [21] Erratum to: Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus
    Lawrence Blonde
    Zinnia T. San Juan
    [J]. Advances in Therapy, 2013, 30 : 306 - 307
  • [22] Fixed-dose combinations: A valuable tool to improve adherence to antihypertensive treatment
    Satsoglou, Sarantis
    Tziomalos, Konstantinos
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2018, 20 (05): : 908 - 909
  • [23] A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension
    Cicero, Arrigo F. G.
    Kuwabara, Masanari
    Borghi, Claudio
    [J]. DRUGS, 2018, 78 (17) : 1783 - 1790
  • [24] A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension
    Arrigo F. G. Cicero
    Masanari Kuwabara
    Claudio Borghi
    [J]. Drugs, 2018, 78 : 1783 - 1790
  • [25] THE PROMISE AND REALITY OF FIXED-DOSE COMBINATIONS WITH RIFAMPICIN
    不详
    [J]. TUBERCLE AND LUNG DISEASE, 1994, 75 (03): : 180 - 181
  • [26] Fixed-dose single tablet antidiabetic combinations
    Bailey, C. J.
    Day, C.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (06): : 527 - 533
  • [27] Fixed-dose combinations: An essential for rational preparation
    Thangaraju, Pugazhenthan
    Varthya, Shoban Babu
    Venkatesan, Sajitha
    [J]. INDIAN JOURNAL OF PHARMACOLOGY, 2021, 53 (02) : 170 - 172
  • [28] From combined therapy to fixed-dose combinations
    Kolos, I. P.
    Boytsov, S. A.
    [J]. CARDIOVASCULAR THERAPY AND PREVENTION, 2008, 7 (04): : 89 - 94
  • [29] Evaluation of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: A Pilot, Dose-Ranging, Randomized Study
    Kellstein, David
    Leyva, Rina
    [J]. DRUGS IN R&D, 2020, 20 (03) : 237 - 247
  • [30] Evaluation of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in the Treatment of Postsurgical Dental Pain: A Pilot, Dose-Ranging, Randomized Study
    David Kellstein
    Rina Leyva
    [J]. Drugs in R&D, 2020, 20 : 237 - 247